Clinical trials: Attention-deficit Hyperactivity
Attention-Deficit/Hyperactivity Disorder (ADHD)
Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD
This open label, flexible-dose study evaluating the safety and efficacy of SPN-812 administered with psychostimulants in children and adolescents (6 to 17 years of age) with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- ADHD (NCT04786990)
- Testing
- SPN-812
- Where
- 17 sites in United States, Puerto Rico
- Volunteers
- 96 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit Hyperactivity Disorder
Lab School Day Study for CONCERTA of Older Children With ADHD
The purpose of this trial is to determine if the study medication, CONCERTA (methylphenidate HCl), is safe and effective in improving academic performance and behavior in children with attention deficit hyperactivity disorder…
- Trial name
- NCT00799409
- Where
- 2 sites in United States
- Volunteers
- 78 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
TBI (Traumatic Brain Injury), Brain Injuries
Brain Markers of Improvements in Cognitive Functioning
Some of the most common, persistent, and disabling consequences of traumatic brain injury affect an individual's ability to achieve personal goals.
- Conditions
- TBI (Traumatic Brain Injury), Brain Injuries, Stress, Attention Deficit
- Trial name
- NCT03490110
- Testing
- State regulation skill training, Treatment-as-usual
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- VA Office of Research and Development
Attention Deficit Hyperactivity Disorder
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting
This Phase 3 pivotal efficacy trial will examine the effects of HLD200 (methylphenidate) in patients aged 6-12 years with ADHD in a naturalistic setting.
- Trial name
- NCT02520388
- Testing
- HLD200 methylphenidate hydrochloride (MPH) Capsules
- Where
- 21 sites in United States
- Volunteers
- 163 people
- Sponsor
- Ironshore Pharmaceuticals and Development, Inc
Attention Deficit Hyperactivity Disorder
Comparison of Atomoxetine Versus Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
This is a two-arm, parallel, randomized, double-blind, placebo-controlled Phase 4 multicenter trial to compare the whole day efficacy of atomoxetine versus placebo in children aged 6 through 12 years with…
- Trial name
- NCT00546910
- Testing
- Atomoxetine
- Where
- 16 sites in Germany
- Volunteers
- 125 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Disorder With Hyperactivity
Open Label, Multicentre Extension Study of Protocol 42603ATT3002 to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Trial 42603ATT3004 is an open-label extension study to clinical trial 42603ATT3002 (NCT00246220). In trial 42603ATT3002 the efficacy and safety of OROS methylphenidate was assessed in adult subjects with Attention Deficit…
- Trial name
- NCT00307684
- Testing
- double blind PR OROS methylphenidate, open label PR OROS methylphenidate
- Where
- 21 sites in France, Germany and 5 more
- Volunteers
- 155 people
- Sponsor
- Janssen-Cilag International NV
Attention Deficit Disorder With Hyperactivity
Comparing the Effectiveness of New Versus Older Treatments for Attention Deficit Hyperactivity Disorder (The NOTA Study)
This study will determine whether two new psychostimulant medications are more effective, tolerable, and acceptable than two older medications for treating attention deficit hyperactivity disorder.
- Trial name
- NCT00889915
- Testing
- Methylphenidate transdermal system, Lisdexamfetamine dimesylate, Osmotic-release oral system methylphenidate (OROS MPH)
- Where
- United States
- Volunteers
- 228 people
- Sponsor
- Duke University
ADHD
Motivated Behavior in Adults With and Without ADHD
To investigate the effects of methylphenidate on motivated behavior in adults with and without ADHD
- Trial name
- MOBE (NCT02630017)
- Where
- 2 sites in United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- University of Arkansas
Attention Deficit Hyperactivity Disorder (ADHD)
12 Month Open Extension of TNS for ADHD.
Participants who exhibit sufficient ADHD symptom improvement in a prior study of active TNS will be invited to continue in a 12-month extension study, designed to collect additional data on long-term response and tolerability and…
- Trial name
- NCT03888391
- Testing
- Active TNS
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- James McGough
Attention-Deficit/Hyperactivity Disorder, Attention Deficit Disorder
Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia
This study seeks to determine, using special sleep tests (polysomnography and actigraphy) if guanfacine extended release is able to improve nighttime sleep in children with ADHD - associated insomnia while improving daytime ADHD…
- Conditions
- Attention-Deficit/Hyperactivity Disorder, Attention Deficit Disorder, Insomnia, Sleep Disorders
- Trial name
- NCT01156051
- Testing
- Guanfacine extended-release tablets
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Children's Specialized Hospital
Attention Deficit Hyperactivity Disorder (ADHD)
Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
The study will evaluate the efficacy of LDX treatment group compared to placebo on the change from Baseline ADHD-RS-IV score at endpoint.
- Trial name
- NCT00735371
- Testing
- LDX 30 mg, LDX 50 mg, LDX 70 mg
- Where
- 45 sites in United States
- Volunteers
- 314 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder
Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder
This study tests the effects of an investigational antipsychotic drug (called OPC-34712) in adults with attention deficit hyperactivity disorder (ADHD) when taken with an approved stimulant medication to explore a possible impact…
- Trial name
- STEP-A (NCT01074294)
- Testing
- OPDC-34712, Stimulant Therapy
- Where
- 35 sites in United States
- Volunteers
- 740 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit/Hyperactivity Disorder, ADHD
L-Threonic Acid Magnesium Salt (L-TAMS) in ADHD
This study is a 12-week, open-label pilot study to test the effects of MMFS-201-301 on cognition and function in adults with ADHD.
- Trial name
- NCT02558790
- Testing
- L-Threonic Acid Magnesium Salt (L-TAMS)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
ADHD
Observational Study to Assess the Frequency of Lidocaine Ineffectiveness in Hard-to-treat ADHD
This work will assess the prevalence in hard-to-treat ADHD of the ineffectiveness of the anesthetic Lidocaine.
- Trial name
- NCT04167189
- Testing
- Lidocaine gel
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- PhenoSolve, LLC
Attention Deficit Hyperactivity Disorder
L-methylfolate Supplementation to OROS-Methylphenidate Pharmacotherapy in ADHD Adults
This pilot study seeks to evaluate initial evidence for the effect of L-methylfolate supplementation to OROS-Methylphenidate pharmacotherapy on ADHD symptoms and associated features in adults with ADHD, as well as tolerability of…
- Trial name
- NCT01853280
- Testing
- L-methylfolate, OROS-Methylphenidate
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Massachusetts General Hospital
ADHD, Attention Deficit Hyperactivity Disorder
Brain Plasticity Underlying Acquisition of New Organizational Skills in Children
Organizational, time management and planning (OTMP) skills deficits are impairing features of developmental disorders, such as Attention Deficit Hyperactive Disorder (ADHD), which compromise school performance and family…
- Conditions
- ADHD, Attention Deficit Hyperactivity Disorder, Neurodevelopmental Disorders
- Trial name
- NCT04108273
- Testing
- Organizational Skills Training
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- NYU Langone Health
Attention Deficit Hyperactivity Disorder (ADHD)
Access to Extended Release Guanfacine HCl for Subjects Who Participated in Studies SPD503-315 or SPD503-316 in Europe
For subjects in Europe that have already participated in either Study SPD503-315 or SPD503-316. This is an extension study that will allow participants access to Extended-release Guanfacine Hydrochloride (HCl) for up to 2 years.
- Trial name
- NCT01500694
- Testing
- Extended-release Guanfacine HCl (Intuniv, SPD503)
- Where
- 60 sites in Austria, Belgium and 11 more
- Volunteers
- 215 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder
Diagnostic Utility of Attention Deficit Hyperactivity Disorder (ADHD) by Brain Activity Flow Patterns Analysis Using Evoked Response Potentials
The purpose of this research study is to study a device called an electroencephalograph (EEG) in the diagnosis of treatment of attention deficit hyperactivity disorder (ADHD) in adults.
- Trial name
- NCT01063153
- Testing
- Osmotic Release Methylphenidate
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
ADHD
Adult Normative Performance of the Quotient ADHD System
This study is being conducted to enhance and extend the clinical utility of the Quotient® ADHD System Adolescent and Adult Version Test by adding large numbers of well-screened controls to the existing Quotient® ADHD System…
- Trial name
- ADHD (NCT01308450)
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- BioBehavioral Diagnostics Company
Attention Deficit Hyperactivity Disorder (ADHD)
NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
This is a randomized, double-blind, placebo-controlled, parallel group, Phase 3 trial to evaluate the safety and efficacy of NT0102 in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 12…
- Trial name
- NCT01835548
- Testing
- NT0102
- Where
- 4 sites in United States
- Volunteers
- 87 people
- Sponsor
- Neos Therapeutics, Inc